Full Press Release Details
Oncolytics Biotech Inc. Collaborators to Present Survival
Data from REO 016 Study in Non-Small Cell Lung Cancer
--Report Near Tripling of Two-Year Survival
Compared to Historical Controls--
CALGARY, Aug. 27, 2015 /CNW/ - Oncolytics Biotech
Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that Dr. Miguel A. Villalona-Calero will make an oral presentation
at International Association for the Study of Lung Cancer (IASLC) 16th World Conference on Lung Cancer on September
9, 2015. The presentation, titled "Oncolytic Reovirus in Combination with Paclitaxel/Carboplatin in NSCLC Patients with Ras
Activated Malignancies, Long Term Results," covers updated results, including longer-term survival data, from the Company's
REO 016 Phase 2 study in Non-Small Cell Lung Cancer (NSCLC).
"Our research collaborators are
noting the two-year survival data from this study, which is high for later-stage patients with recurrent or metastatic disease,"
said Dr. Matt Coffey, COO of Oncolytics. "As with our REO 017 clinical study that treated pancreatic cancer patients with
gemcitabine and REOLYSIN , there was a clear overall survival benefit with apparent limited impact on progression
free survival, which is generally characteristic of immune involvement in outcomes."
Highlights of the data to be presented
For comparison, the Company is referring
to historical control data as per Schiller et al., 2002, which reported a median PFS of 3.1 months, median OS of 8.1 months, one-year
survival rates of 34%, and two-year survival rates of 11%. There were 290 patients treated with carboplatin and paclitaxel, 86%
of which were Stage IV and 14% Stage IIIB.
Of the 35 patients evaluable for clinical
response in the REO 016 study, 11 patients (5 Kras mutant) had a partial response (PR), 20 had stable disease (SD) and four
had progressive disease by RECIST for an objective response rate (ORR) of 31%. Four patients with SD had a >40% PET standardized
update value reduction after two cycles, yielding an ORR considering PET of 43%.
REO 016 is a U.S. single arm, two-stage,
open-label, Phase 2 study of REOLYSIN given intravenously with paclitaxel and carboplatin every three weeks. Patients
received four to six cycles of paclitaxel and carboplatin in conjunction with REOLYSIN , at which time REOLYSIN
may have been continued as a monotherapy. As previously disclosed, the primary objectives of the trial were to determine the ORR
of REOLYSIN in combination with paclitaxel and carboplatin in patients with metastatic or recurrent NSCLC with
Kras or EGFR-activated tumours, and to measure PFS at six months. The secondary objectives were to determine the median
survival and duration of PFS in patients, and to evaluate the safety and tolerability of REOLYSIN in combination
with paclitaxel and carboplatin in this patient population.
A copy of the abstract will be available
on the Oncolytics website at: http://www.oncolyticsbiotech.com/for-investors/presentations and is also available on the conference
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology
company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes
a variety of later-stage, randomized human trials in various indications using REOLYSIN , its proprietary formulation
of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking
statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the Phase II single-arm
clinical trial in NSCLC, future trials in this indication, and the Company's belief as to the potential of REOLYSIN
as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ
materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of
funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment,
the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and
trials, the Company's ability to successfully commercialize REOLYSIN , uncertainties related to the research, development
and manufacturing of pharmaceuticals, changes in technology, general changes to the economic environment and uncertainties related
to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities
commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors should
consider statements that include the words "believes", "expects", "anticipates", "intends",
"estimates", "plans", "projects", "should", or other expressions that are predictions of
or indicate future events or trends, to be uncertain and forward-looking. Investors are cautioned against placing undue reliance
on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by
SOURCE Oncolytics Biotech Inc.
For further information: TMX Equicom, Nick Hurst, 300 5th
Ave. SW, 10th Floor, Calgary, Alberta T2P 3C4, Tel: 403.218.2835, Fax: 403.218.2830, nhurst@tmxequicom.com; TMX Equicom, Michael
Moore, San Diego, CA, Tel: 858.886.7813, mmoore@tmxequicom.com; Dian Griesel, Inc., Susan Forman, 335 West 38th Street, 3rd Floor,
New York, NY 10018, Tel: 212.825.3210, Fax: 212.825.3229, sforman@dgicomm.com
CO: Oncolytics Biotech Inc.
CNW 06:30e 27-AUG-15